Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 1, 2011, Pages 93-97

  Mendes, Rodrigo E ^a   Sader, Helio S ^a   Farrell, David J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Europe; Glycopeptides; Lipoglycopeptide; Staphylococcus spp.; Telavancin

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; LINEZOLID; METICILLIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; EUROPE; HOSPITAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; SENTINEL SURVEILLANCE; STAPHYLOCOCCUS;

EID: 80051630585     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.05.012     Document Type: Article

References (21)

1. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - 8th edition. M07-A8 2009, Wayne, PA: CLSI. 8th ed.
2. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing 2011.
3. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 2008, 52:2383-2388.
4. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 2008, 62:116-121.
5. Dunbar L.M., Tang D.M., Manausa R.M. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther. Clin. Risk Manag. 2008, 4:235-244.
6. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, March 2011 2011, Available at. http://www.eucast.org.
7. Haque N.Z., Zuniga L.C., Peyrani P., Reyes K., Lamerato L., Moore C.L., Patel S., Allen M., Peterson E., Wiemken T., Cano E., Mangino J.E., Kett D.H., Ramirez J.A., Zervos M.J. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138:1356-1362.
8. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Int. Med. 2006, 166:2138-2144.
9. Karlowsky J.A., Adam H.J., Poutanen S.M., Hoban D.J., Zhanel G.G. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 2011, 69:342-347.
10. Krause K.M., Renelli M., Difuntorum S., Wu T.X., Debabov D.V., Benton B.M. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 2008, 52:2647-2652.
11. Leonard S.N., Vidaillac C., Rybak M.J. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2009, 53:2928-2933.
12. Lunde C.S., Hartouni S.R., Janc J.W., Mammen M., Humphrey P.P., Benton B.M. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 2009, 53:3375-3383.
13. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 2009, 47:1640-1644.
14. Putnam S.D., Sader H.S., Moet G.J., Mendes R.E., Jones R.N. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn. Microbiol. Infect. Dis. 2010, 67:359-368.
15. Rubinstein E., Lalani T., Corey G.R., Kanafani Z.A., Nannini E.C., Rocha M.G., Rahav G., Niederman M.S., Kollef M.H., Shorr A.F., Lee P.C., Lentnek A.L., Luna C.M., Fagon J.Y., Torres A., Kitt M.M., Genter F.C., Barriere S.L., Friedland H.D., S tryjewski M.E. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin. Infect. Dis. 2011, 52:31-40.
16. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 2004, 42:2398-2402.
17. Saravolatz L.D., Stein G.E., Johnson L.B. Telavancin: a novel lipoglycopeptide. Clin. Infect. Dis. 2009, 49:1908-1914.
18. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., Alamo D., Ortega M., Lopez J., Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
19. Stryjewski M.E., Graham D.R., Wilson S.E., O'Riordan W., Young D., Lentnek A., Ross D.P., Fowler V.G., Hopkins A., Friedland H.D., Barriere S.L., Kitt M.M., Corey G.R. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 2008, 46:1683-1693.
20. VIBATIV Package Insert Theravance, Inc., South San Francisco, CA Available at. http://www.vibativ.com.
21. Yoon Y.K., Kim J.Y., Park D.W., Sohn J.W., Kim M.J. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 2010, 65:1015-1018.